Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Recover your password.
A password will be e-mailed to you.
PARIS, Nov. 08, 2022 (GLOBE NEWSWIRE) — In response to the shortage of molybdenum-99 (Mo-99) that the nuclear medicine community faces in November 2022, the world’s major processing facilities and reactors confirm the details of their plans to continue serve the 40 million patients a year who undergo technetium-99m (Tc-99m) based SPECT scans to diagnose life-critical diseases. This shortage will also impact Xe-133, and to some extent I-131.
Despite the industry’s robust supply chain security programs in place, the shortage in November is a result of planned outages and unscheduled maintenance programs at individual facilities that unfortunately have overlapped in November. To address this anticipated shortage, a number of measures are underway at processing facilities and reactors to ensure a minimum of disruption to patients, including:
Reliability of Supply Initiatives
The reactors the nuclear medicine community relies on for production of medical radionuclides and Mo-99 processors meet regularly under the flag of Nuclear Medicine Europe in order to align planning of reactor schedules. While this scheduling ensures the best possible coverage for the reliable production of these radionuclides, it cannot predict unplanned outages. This scheduling also helps to keep reserve capacity available throughout the year.
This shortage of Mo-99 follows more than ten years of Mo-99 supply chain resilience with longer-term initiatives in place and investments to ensure a reliable supply of Mo-99 for hospitals and nuclear pharmacies – ultimately serving the patients awaiting diagnosis. These initiatives include:
A History of Mo-99 Supply Reliability
These longer-term initiatives have contributed to a robust supply chain and reliable supply of Mo-99 over the past ten years, as evidenced by:
Additional Planned Reactor Capacity
Current industry players are in a strong position to reliably supply the needs of patients over the long-term, despite the anticipated supply issues in the next few weeks. Resilience of the current Mo-99 supply chain is further evidenced by additional reactor capacity that will emerge in coming years, creating significant reserve capacity:
Despite the near-term shortage of Mo-99, a supply chain with proven resilience demonstrated over the past ten years, additional planned reactor capacity coming online, and measures in place ensure a minimum of disruption to patients together demonstrate the commitment of the world’s major processing facilities and reactors in delivering Mo-99 for the benefit of patients.
– ends –
For more information:
Ross Bethell
VP, Head of Global Communications
communications@curiumpharma.com
About Curium
Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit curiumpharma.com.
Get real time updates directly on you device, subscribe now.